Great Diamond Partners
VRTX icon

Great Diamond Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Great Diamond Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$694K Sell
1,327
-19
-1% -$9.7K 0.12% 145
2026
Q2 		$669K Sell
1,346
-58
-4% -$25.7K 0.11% 146
2026
Q1 		$627K Sell
1,404
-12
-0.8% -$5.6K 0.12% 143
2025
Q4 		$642K Buy
1,416
+44
+3% +$19K 0.12% 141
2025
Q3 		$537K Sell
1,372
-404
-23% -$169K 0.1% 151
2025
Q2 		$791K Buy
1,776
+423
+31% +$195K 0.17% 126
2025
Q1 		$656K Buy
1,353
+338
+33% +$158K 0.18% 100
2024
Q4 		$409K Sell
1,015
-12
-1% -$5.56K 0.11% 123
2024
Q3 		$478K Sell
1,027
-682
-40% -$328K 0.12% 119
2024
Q2 		$801K Sell
1,709
-34
-2% -$14.8K 0.19% 102
2024
Q1 		$729K Sell
1,743
-16
-0.9% -$6.76K 0.17% 112
2023
Q4 		$716K Buy
1,759
+21
+1% +$7.76K 0.18% 114
2023
Q3 		$604K Buy
1,738
+1
+0.1% +$350 0.16% 119
2023
Q2 		$611K Buy
1,737
+139
+9% +$46.8K 0.16% 118
2023
Q1 		$503K Sell
1,598
-203
-11% -$60.9K 0.15% 125
2022
Q4 		$520K Sell
1,801
-116
-6% -$35.4K 0.16% 119
2022
Q3 		$555K Sell
1,917
-83
-4% -$23.9K 0.19% 107
2022
Q2 		$563K Sell
2,000
-483
-19% -$129K 0.19% 104
2022
Q1 		$647K Sell
2,483
-153
-6% -$36.3K 0.18% 104
2021
Q4 		$578K Sell
2,636
-38
-1% -$7.39K 0.15% 119
2021
Q3 		$485K Buy
+2,674
New +$522K 0.13% 123
2020
Q1 		– Sell
-34
Closed -$7K – 590
2019
Q4 		$7K Buy
+34
New +$6.88K ﹤0.01% 584

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Great Diamond Partners's VRTX Position: Q3 2026 in Review

Great Diamond Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 1.4% in Q3 2026, selling an estimated $9.7K and leaving 1,327 shares worth $694K. The position accounts for 0.12% of the portfolio, ranked #145.

Great Diamond Partners first reported a position in VRTX in Q4 2019 and has held it in 22 quarters since. The position peaked at $801K in Q2 2024. 1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Great Diamond Partners held 1,327 shares of Vertex Pharmaceuticals worth $694K as of Q3 2026.
  • Great Diamond Partners sold 19 Vertex Pharmaceuticals shares in Q3 2026, an estimated $9.7K.
  • Vertex Pharmaceuticals made up 0.12% of Great Diamond Partners's portfolio in Q3 2026, its #145 holding.
  • Great Diamond Partners first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 22 quarters since.
  • Great Diamond Partners's Vertex Pharmaceuticals position peaked at $801K in Q2 2024.
  • 1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Great Diamond Partners's 13F filing for Q3 2026, filed 13 Oct 2026.